Search
for
Sort by
Research 331–360 of 1000+
- Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?
- LAM/TSC Cell Migration to Uterus in an Experimental Model of Lymphangioleiomyomatosis. Regulation by Anti-Epidermal Growth Factor Receptor Antibody and Rapamycin
- An Evaluation of Generic and Disease‐Specific Patient‐Reported Outcome Measures to Assess the Impact of Percentage of Scalp Hair Loss on Health‐Related Quality of Life in a European Population
- Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique
- Frontal Fibrosing Alopecia and Reproductive Health: Assessing the Role of Sex Hormones in Disease Development
- Surgical Correction of cicatricial Entropion in cattle: Two cases
- Analysis of changes in microRNA expression profiles in response to the troxerutin-mediated antioxidant effect in human dermal papilla cells
- Integrated Business Intelligent System for E-Health: A Case for Dermatology Diseases
- Camellia nitidissima Flower Extract Alleviates Dermal Papilla Cell Dysfunction by Regulating 11β-HSD1 and the TGF-β2/Smad and Wnt/β-Catenin Pathways
- Innovation and Biodiversity: Patent Trends in Therapeutic and Cosmetic Use of Scientifically Relevant Pantanal Plants
- Dermatologists’ Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the United Arab Emirates
- Real-world Burden of Disease and Clinical Characteristics of Alopecia Areata Among Adults in Brazil: Results from a Cross-sectional Survey
- Anti-Particulate Adhesion Efficacy of a Cosmetic Product: A Controlled In Vivo Study Using a Patented Exposure Chamber
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- Hirsutism Beyond PCOS: Genome-wide Evidence for Genetic Factors
- Industry updates in advanced therapy medicinal products and regenerative medicine – March 2026
- Nanotechnology-Based Strategies for Hair Regeneration: Mechanistic Insights and Translational Perspectives for Androgenetic Alopecia
- Nanotechnology-Based Strategies for Hair Regeneration: Mechanistic Insights and Translational Perspectives for Androgenetic Alopecia
- Anti-aging effect of <i>Grateloupia elata</i> extract in skin
- Human umbilical cord mesenchymal stem cell-derived exosomes enhance follicular regeneration in androgenetic alopecia via activation of Wnt/β-catenin pathway
- Hair regeneration in androgenetic alopecia using secretome of adipose-derived stem cells (ADSC) and minoxidil: a comparative study of three groups
- Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches
- Standardization, Validation, and Application of a Rapid and Reliable HPLC-UV Method for the Determination of Minoxidil in Hair Growth Products
- Recent approaches of antibody therapeutics in androgenetic alopecia
- Correlating Cicatricial Alopecia and Cardiovascular Risk: Emerging Insights
- Identification of SLC40A1, LCN2, CREB5, and SLC7A11 as ferroptosis-related biomarkers in alopecia areata through machine learning
- Degree of Alignment Between Japanese Patients and Physicians on Alopecia Areata Disease Severity and Treatment Satisfaction: A Real-World Survey
- Eflornithine Hydrochloride-Loaded Electrospun Nanofibers as a Potential Face Mask for Hirsutism Application
- Combination of adipose-derived stem cell conditioned media and minoxidil for hair regrowth in male androgenetic alopecia: a randomized, double-blind clinical trial